N. Uemura
University of California, San Francisco
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by N. Uemura.
Clinical Pharmacology & Therapeutics | 2004
N. Uemura; M. R. Harkey; Rajneesh P. Nath; G. L. Henderson; John Mendelson; Reese T. Jones
Sweat patch analysis is extensively used for drug abuse monitoring. The present study investigates how cocaine migrates to sweat patches. In the cumulative collection model, the drug absorption rate in patches should be proportional to the drug concentration in the preceding disposition compartment if drug back‐transfer is negligible. Therefore, we measured the slopes of cocaine concentration curves in patches as a marker for absorption rate (into patches) after a single dose of cocaine‐d5 (1mg/kg over 60 min) in healthy cocaine users (n=5). Patches were placed on the back of subjects prior to drug administration and removed at 0–72 hr postdose. Blood and interstitial fluid (skin blister fluid) were collected up to 72 hr. Patch cocaine levels showed semi‐cumulative collection with peaks between 8 and 48 hr. Cocaine levels in plasma and interstitial fluid peaked at 1.0±0 and 5.3±0.6 hours postdose, respectively, suggesting a delayed cocaine disposition in the interstitial fluid. Similarly, patch cocaine absorption was delayed with rate peaks at 4.3±2.9 hr postdose. Tmax for plasma benzoylecgonine (BE) was 5.0±2.4 hr. BE also showed a delayed peak in the interstitial fluid at 11.3±11.0 hr post, and the highest BE absorption in patches was observed in a similar time range of 12.4±4.9 hr. Cocaine and its metabolite migrate into patches in a time period that coincides with Tmax in interstitial fluid. Cocaine seems to travel from plasma to sweat patches via interstitial fluid.
Clinical Pharmacology & Therapeutics | 2005
N. Uemura; Debra S. Harris; Rajneesh P. Nath; E. Fernandez; Peyton Jacob; Everhart Et; Reese T. Jones; John Mendelson
Methamphetamine has a chiral structure. The aim of the present study was to assess the pharmacokinetics of methamphetamine enantiomers in humans.
Clinical Pharmacology & Therapeutics | 2003
N. Uemura; A.P. Manari; Rajneesh P. Nath; Debra S. Harris; Reese T. Jones; John Mendelson
Clinical Pharmacology & Therapeutics (2003) 73, P91–P91; doi:
Clinical Pharmacology & Therapeutics | 2003
John Mendelson; Elyse Foster; E. Ryan; N. Uemura; Rajneesh P. Nath; Reese T. Jones
Clinical Pharmacology & Therapeutics (2003) 73, P36–P36; doi:
Clinical Pharmacology & Therapeutics | 2003
A.P. Manari; N. Uemura; Rajneesh P. Nath; Debra S. Harris; Reese T. Jones; John Mendelson
Clinical Pharmacology & Therapeutics (2003) 73, P35–P35; doi:
Journal of Analytical Toxicology | 2004
N. Uemura; Rajneesh P. Nath; Martha R. Harkey; Gary L. Henderson; John Mendelson; Reese T. Jones
Journal of Analytical Toxicology | 2002
Laeben Lester; N. Uemura; John I. Ademola; Martha R. Harkey; Rajneesh P. Nath; Seong Jin Kim; Elena Jerschow; Gary L. Henderson; John Mendelson; Reese T. Jones
Quality Assurance Journal | 2005
Kiyomi Hirayama; Naohisa Fukuda; Hitoshi Satoh; Katsumi Itoh; Kiyoshi Chiba; Yutaka Nakae; Masayuki Takezawa; Kuniko Gotoh; N. Uemura
Clinical Pharmacology & Therapeutics | 2001
N. Uemura; L. Lester; Rajneesh P. Nath; John Mendelson; M. R. Harkey; G. L. Henderson; Reese T. Jones
Clinical Pharmacology & Therapeutics | 2001
John Mendelson; A. S. Dearborn; N. Uemura; L. Lester; N. Chiang; Peyton Jacob; Reese T. Jones